{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:29:39Z","timestamp":1793867379255,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.joms.2026.07.008","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:24:25Z","timestamp":1784071465000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Should Teriparatide Be Part of Our Clinical Armamentarium in the Management of Medication-Related Osteonecrosis of the Jaw? A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1575-722X","authenticated-orcid":false,"given":"Sam","family":"Sheridan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahm","family":"Rafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1697-6481","authenticated-orcid":false,"given":"Nisarg","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2026.07.008_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2231-0762.178742","article-title":"Medication-related osteonecrosis of the jaw: clinical and practical guidelines","volume":"6","author":"Rosella","year":"2016","journal-title":"J Int Soc Prev Community Dent"},{"issue":"5","key":"10.1016\/j.joms.2026.07.008_bib2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the Jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2026.07.008_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of osteonecrosis of the jaws","volume":"27","author":"Aghaloo","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.joms.2026.07.008_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2026.07.008_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijom.2009.11.014","article-title":"Surgical management of bisphosphonate-induced osteonecrosis of the jaws","volume":"39","author":"Williamson","year":"2010","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2026.07.008_bib6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jcms.2018.12.014","article-title":"Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study","volume":"47","author":"Ristow","year":"2019","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2026.07.008_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.oooo.2019.08.004","article-title":"Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw","volume":"128","author":"Heifetz-Li","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.joms.2026.07.008_bib8","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2026.07.008_bib9","first-page":"499","article-title":"Teriparatide in the management of osteoporosis","volume":"2","author":"Bodenner","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.joms.2026.07.008_bib10","series-title":"StatPearls [Internet]","article-title":"Teriparatide","author":"Vall","year":"2025"},{"key":"10.1016\/j.joms.2026.07.008_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrd1068","article-title":"Teriparatide","volume":"2","author":"Berg","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.joms.2026.07.008_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2023.111161","article-title":"Teriparatide-induced alleviation of medication-related osteonecrosis of the jaw: potential molecular mechanisms","volume":"179","author":"Yu","year":"2023","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.joms.2026.07.008_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","article-title":"Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1\u201334)]","volume":"65","author":"Harper","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2026.07.008_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/odi.13275","article-title":"The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice","volume":"26","author":"Yu","year":"2020","journal-title":"Oral Dis"},{"issue":"71","key":"10.1016\/j.joms.2026.07.008_bib15","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.joms.2026.07.008_bib17","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.joms.2026.07.008_bib18","series-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6","author":"Higgins","year":"2022"},{"key":"10.1016\/j.joms.2026.07.008_bib19","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00198-014-2622-8","article-title":"Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw","volume":"25","author":"Kim","year":"2014","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.joms.2026.07.008_bib20","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1111\/odi.14801","article-title":"Effects of daily versus weekly teriparatide for medication-related osteonecrosis of the jaw: a case-control study","volume":"30","author":"Kim","year":"2024","journal-title":"Oral Dis"},{"issue":"9","key":"10.1016\/j.joms.2026.07.008_bib21","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.joms.2026.07.008_bib22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bjoms.2021.10.004","article-title":"Effective ancillary role and long-term course of daily or weekly teriparatide treatment on refractory medication-related osteonecrosis of the jaw: a clinical case series","volume":"60","author":"Yoshiga","year":"2022","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2026.07.008_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.joms.2026.07.008_bib24","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.4317\/medoral.19458","article-title":"Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide","volume":"19","author":"Pelaz","year":"2014","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"12","key":"10.1016\/j.joms.2026.07.008_bib25","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/jbmr.3237","article-title":"Short-term teriparatide and recombinant human bone morphogenetic Protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study","volume":"32","author":"Jung","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2026.07.008_bib26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00198-019-05199-w","article-title":"A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration","volume":"31","author":"Ohbayashi","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2026.07.008_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.joms.2015.07.005","article-title":"Histopathological effects of teriparatide in medication-related osteonecrosis of the jaw: an animal study","volume":"74","author":"Keskinruzgar","year":"2016","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2026.07.008_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2026.07.008_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus"},{"key":"10.1016\/j.joms.2026.07.008_bib30","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","volume":"363","author":"Bashutski","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2026.07.008_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6040379","article-title":"The effect of teriparatide on fracture healing of osteoporotic patients: a meta-analysis of randomized controlled trials","volume":"2016","author":"Lou","year":"2016","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.joms.2026.07.008_bib32","article-title":"Efficacy and safety of teriparatide in improving fracture healing and callus formation: a systematic review","volume":"15","author":"Puvvada","year":"2023","journal-title":"Cureus"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239126007937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239126007937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:19:39Z","timestamp":1793866779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239126007937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"alternative-id":["S0278239126007937"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2026.07.008","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should Teriparatide Be Part of Our Clinical Armamentarium in the Management of Medication-Related Osteonecrosis of the Jaw? A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2026.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Association of Oral and Maxillofacial Surgeons.","name":"copyright","label":"Copyright"}]}}